• 1.

    Doitsh, G. & Greene, W.C. Investigation of how CD4 T cells are lost during HIV infection. Cell Host Microbe 19, 280-291 (2016).

  • Second

    Churchill, M.J., Deeks, S.G., Margolis, D.M., Siliciano, R.F. & Swanstrom, R. HIV reservoirs: what, where and how to target them. Nat. Rev. Microbiol, 14, 55-60 (2016).

  • Third

    Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. nature 543, 559-563 (2017).

  • 4th

    Gautam, R. et al. A single injection of crystallizable fragment-domain-modified antibodies triggers permanent protection against SHIV infection. Nat. med, 24, 610-616 (2018).

  • 5th

    Schoofs, T. et al. HIV-1 therapy with the monoclonal antibody 3BNC117 triggers host immune responses to HIV-1. science 352, 997-1001 (2016).

  • 6th

    Caskey, M. et al. Viremia was suppressed in HIV-1-infected humans by largely neutralizing the antibody 3BNC117. nature 522, 487-491 (2015).

  • 7th

    Lynch, R.M. et al. Virological effects of extensive neutralization of antibody VRC01 administration during chronic HIV-1 infection. Sci. Translation Med, 7, 319ra206 (2015).

  • 8th.

    Caskey, M. et al. The antibody 10-1074 suppresses viremia in HIV-1 infected individuals. Nat. med, 23, 185-191 (2017).

  • 9th

    Scheid, J.F. et al. The HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. nature 535, 556-560 (2016).

  • 10th

    Li, J.Z. et al. The size of the expressed HIV reservoir predicts the timing of the viral rebound after treatment interruption. AIDS 30, 343-353 (2016).

  • 11th

    Bar, K.J. et al. Effect of the HIV antibody VRC01 on the viral rebound after treatment interruption. N. Engl. J. Med, 375, 2037-2050 (2016).

  • 12th

    Shingai, M. et al. Passive transmission of modest titers of potent and largely neutralizing monoclonal anti-HIV antibodies block SHIV infection in macaques. J. Exp. Med, 211, 2061-2074 (2014).

  • 13th

    Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. nature 533, 105-109 (2016).

  • 14th

    Klein, F. et al. HIV therapy by a combination of largely neutralizing antibodies in humanized mice. nature 492, 118-122 (2012).

  • 15th

    Horwitz, J.A. et al. HIV-1 suppression and long-term control by combining single largely neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538-16543 (2013).

  • 16th

    Shingai, M. et al. Antibody-mediated immunotherapy of chronically SHIV infected macaques suppresses viremia. nature 503, 277-280 (2013).

  • 17th

    Trkola, A. et al. Delay in the recurrence of HIV-1 after cessation of antiretroviral therapy by passive transfer of neutralizing human antibodies. Nat. med, 11, 615-622 (2005).

  • 18th

    Mehandru, S. et al. Concomitant passive immunotherapy in type 1 infected humans who are infected with the immunodeficiency virus and who have been treated during an acute and an early infection with antiviral therapy. J. Virol, 81, 11016-11031 (2007).

  • 19th

    Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for the standardized evaluation of neutralizing antibodies to HIV-1. J. Immunol. methods 409, 131-146 (2014).

  • 20th

    Cohen, Y. Z. et al. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J. Exp. Med, 215, https://doi.org/10.1084/jem.20180936 (2018).

  • 21st

    Robertson, D.L., Sharp, P.M., McCutchan, F.E. & Hahn, B.H. Recombination in HIV-1. nature 374, 124-126 (1995).

  • 22nd

    Rothenberger, M.K. et al. A large number of Rebounding / Founder HIV variants are caused by multifocal infection in lymphoid tissues after treatment interruption. Proc. Natl Acad. Sci. USA 112, E1126-E1134 (2015).

  • 23rd

    Kearney, M.F. et al. Absence of detectable HIV-1 molecular evolution during antiretroviral suppressive therapy. PLoS-Pathog, 10, e1004010 (2014).

  • 24th

    Lorenzi, J.C. et al. Paired quantitative and qualitative assessment of replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proc. Natl Acad. Sci. USA 113, E7908-E7916 (2016).

  • 25th

    Wang, Z. et al. Extended cellular clones carrying replication-competent HIV-1 persist, grow, and lose. Proc. Natl Acad. Sci. USA 115, E2575-E2584 (2018).

  • 26th

    Hosmane, N.N. et al. Proliferation of latently infected CD4+ T-cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics. J. Exp. Med, 214, 959-972 (2017).

  • 27th

    Crooks, A.M. et al. Precise Quantification of the HIV-1 Latent Reservoir: Implications for Eradication Strategies. J. Infect. Dis, 212, 1361-1365 (2015).

  • 28th

    Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. immunity 10, 431-438 (1999).

  • 29th

    Scheid, J.F. et al. A method for identifying HIV gp140 binding of memory B cells in human blood. J. Immunol. methods 343, 65-67 (2009).

  • 30th

    Escolano, A., Dosenovic, P. & Nussenzweig, M. C. Advances Towards Active or Passive HIV-1 Inoculation. J. Exp. Med, 214, 3-16 (2017).

  • 31st

    Kwong, P.D. & Mascola, J.R. HIV-1 vaccines based on antibody identification, B cell ontogenesis and epitope structure. immunity 48, 855-871 (2018).

  • 32nd

    Lu, C.L. et al. Increased clearance of HIV-1-infected cells by largely neutralizing antibodies to HIV-1 in vivo. science 352, 1001-1004 (2016).

  • 33rd

    Walker, B.D. & Yu. X. G. Unravel the mechanisms of permanent control of HIV-1. Nat. Rev. Immunol, 13, 487-498 (2013).

  • 34th

    Colby, D.J. et al. Rapid HIV-RNA rebound after antiretroviral treatment interruption in individuals who have been permanently suppressed in Fiebig I acute HIV infection. Nat. med, 24, 923-926 (2018).

  • 35th

    Sáez-Cirion, A. et al. Follow-up treatment HIV-1 controller with a long-term virologic remission after interruption of early-onset antiretroviral therapy ANRS VISCONTI study. PLoS-Pathog, 9, e1003211 (2013).

  • 36th

    Sneller, M.C. et al. A randomized, controlled trial on the safety / efficacy of a therapeutic vaccine in HIV-infected individuals who initiated antiretroviral therapy early in the infection. Sci. Translation Med, 9, eaan8848 (2017).

  • 37th

    Fidler, S. et al. Virological blips and predictors of viral control after treatment after termination of ART began with primary HIV infection. J. Acquir. Immunodeficiency. Syndr, 74, 126-133 (2017).

  • 38th

    Martin, G.E. et al. Post-treatment or treated controller? Viral remission in treated and untreated primary HIV infection. AIDS 31, 477-484 (2017).

  • 39th

    Cohn, L.B. et al. Clonal CD4+ T cells in the latent HIV-1 reservoir show a pronounced gene profile upon reactivation. Nat. med, 24, 604-609 (2018).

  • 40th

    Maldarelli, F. et al. Specific HIV integration sites are associated with clonal expansion and persistence of infected cells. science 345, 179-183 (2014).

  • 41st

    Wagner, T.A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. science 345, 570-573 (2014).

  • 42nd

    Cohn, L.B. et al. HIV-1 integration landscape with latent and active infection. cell 160, 420-432 (2015).

  • 43rd

    Halper-Stromberg, A. et al. Highly neutralizing antibodies and viral inducers reduce the rebound of HIV-1 latent reservoirs in humanized mice. cell 158, 989-999 (2014).

  • 44th

    Ko, S.Y. et al. Improved neonatal Fc receptor function enhances protection against primate SHIV infection. nature 514, 642-645 (2014).

  • 45th

    Gaudinski, M.R. et al. Safety and pharmacokinetics of the Fc-modified human monoclonal HIV-1 antibody VRC01LS: an open-label, phase 1 clinical trial in healthy adults. PLoS Med, 15, e1002493 (2018).

  • 46th

    Salazar-Gonzalez, J.F. et al. Deciphering the transmission of human immunodeficiency virus type 1 and diversification of the early envelope by single genome amplification and sequencing. J. Virol, 82, 3952-3970 (2008).

  • 47th

    Kirchherr, J.L. et al. High throughput functional analysis of HIV-1 env Genes without cloning. J. Virol. methods 143, 104-111 (2007).

  • 48th

    Larkin, M.A. et al. Clustal W and Clustal X Version 2.0. Bioinformatics 23, 2947-2948 (2007).

  • 49th

    Guindon, S. et al. New Algorithms and Methods for Estimating Phylogenies with Maximum Likelihood: Assessing the Performance of PhyML 3.0. Syst. Biol, 59, 307-321 (2010).

  • 50th

    Stamatakis, A. RAxML Version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312-1313 (2014).


    Please enter your comment!
    Please enter your name here

    This site uses Akismet to reduce spam. Learn how your comment data is processed.